Focus: Aptevo Therapeutics is a Seattle-based public biotech focused on bispecific antibodies for oncology and hematology. The company operates at clinical-stage with a diversified pipeline across blood cancers and solid tumors.
Profile data last refreshed 20h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Aptevo Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Aptevo Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Aptevo Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
+1 more
Aptevo Therapeutics Inc. (APVO) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Aptevo Therapeutics Inc. (APVO) Shareholding Pattern – Promoters, FIIs & DIIs valueresearchonline.com
Aptevo Therapeutics (APVO) quietly closes private funding round - Stock Titan
Aptevo Therapeutics (APVO) quietly closes private funding round Stock Titan
Form 8K Aptevo Therapeutics Inc For: 14 August By Investing.com - Investing.com UK
Form 8K Aptevo Therapeutics Inc For: 14 August By Investing.com Investing.com UK
Aptevo Therapeutics (APVO): CVI and Heights disclose 6.3% warrant-based stake - Stock Titan
Aptevo Therapeutics (APVO): CVI and Heights disclose 6.3% warrant-based stake Stock Titan
New Aptevo warrants for 4.3M shares await stockholder approval - Stock Titan
New Aptevo warrants for 4.3M shares await stockholder approval Stock Titan
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds - ACCESS Newswire
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds ACCESS Newswire
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Constructing the cure: engineering the next wave of antibody and cellular immune therapies.
The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo